Dr Tarantino on the Potential Significance of SGN-B7H4V in Breast Cancer
Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.
Dr Tarantino on Understanding the Role of ADC Payloads in Breast Cancer
Paolo Tarantino, MD, discusses the importance of understanding the role that payloads play in treatment with antibody-drug conjugates in breast cancer.
Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Dr Tarantino on the Use of ADCs in HR+ Breast Cancer
Paolo Tarantino, MD, discusses the use of antibody drug conjugates in patients with hormone receptor-positive breast cancer.
Dr Tarantino on Patient Awareness of the Platinum Shortage in Breast Cancer
Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.
Dr Tarantino on the Effects of Platinum Chemotherapy Shortages in Breast Cancer
Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.
Dr Tarantino on the Impact of Emerging ADCs in HR+ Breast Cancer
Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.
Dr Tarantino on the Expansion of Treatment Options Post-CDK4/6 Inhibition in HR+ Breast Cancer
Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.
Emerging Concepts in mBC Treatment
Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.
Investigational ADCs for Treatment of TNBC
Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.
The Role of ADCs in the Treatment of TNBC
Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.
Standard Practices for the Management of Triple-Negative Breast Cancer (TNBC)
Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.
The Role of Capivasertib in ER+/HER- mBC
Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.
Use of Second-Generation Oral SERDs in ER+/HER2- mBC
Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.
Standards of Care in the Frontline Treatment of ER+/HER2- mBC
Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.
Overview of ER+/HER2- Metastatic Breast Cancer (mBC)
Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.
Dr. Tarantino on the Impact of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer
Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.
Dr Tarantino on Second-line Treatment Selection in HER2+ Metastatic Breast Cancer
Paolo Tarantino, MD, researcher, the European Institute of Oncology; clinical research fellow, Dana-Farber Cancer Institute, discusses the options available in the second line for patients with HER2-positive metastatic breast cancer.
Dr. Tarantino on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer
Paolo Tarantino, MD, discusses the importance of the phase 3 DESTINY-Breast04 trial in HER2-low breast cancer.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512